Amicus Therapeutics (NASDAQ:FOLD) PT Set at $18.00 by HC Wainwright

HC Wainwright set a $18.00 price objective on Amicus Therapeutics (NASDAQ:FOLD) in a report issued on Monday, TipRanks reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently commented on the stock. BidaskClub cut shares of ZIX from a strong-buy rating to a buy rating in a research report on Friday, June 7th. Cantor Fitzgerald reaffirmed an overweight rating and issued a $19.00 target price (down from $20.00) on shares of Amicus Therapeutics in a research report on Wednesday, June 5th. Robert W. Baird assumed coverage on shares of Rocket Pharmaceuticals in a research report on Monday, April 22nd. They issued an outperform rating for the company. Zacks Investment Research cut shares of Inflarx from a buy rating to a hold rating in a research report on Friday, May 3rd. Finally, Janney Montgomery Scott assumed coverage on shares of Amicus Therapeutics in a research report on Friday, April 5th. They issued a buy rating and a $13.91 target price for the company. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $18.06.

FOLD traded up $0.11 during trading on Monday, hitting $12.69. 1,717,289 shares of the stock traded hands, compared to its average volume of 3,046,599. The company has a market cap of $2.89 billion, a price-to-earnings ratio of -9.54 and a beta of 1.77. The company has a debt-to-equity ratio of 0.45, a current ratio of 7.33 and a quick ratio of 7.21. The company has a 50-day moving average price of $11.99. Amicus Therapeutics has a 12-month low of $8.27 and a 12-month high of $16.27.



Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.09). Amicus Therapeutics had a negative return on equity of 64.11% and a negative net margin of 386.18%. The company had revenue of $34.00 million during the quarter, compared to analysts’ expectations of $37.82 million. The firm’s revenue for the quarter was up 103.6% on a year-over-year basis. As a group, equities research analysts expect that Amicus Therapeutics will post -1.29 EPS for the current fiscal year.

In related news, Director Michael Raab sold 5,000 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $11.16, for a total value of $55,800.00. Following the completion of the transaction, the director now directly owns 13,895 shares in the company, valued at approximately $155,068.20. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO John F. Crowley sold 20,000 shares of the stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $13.51, for a total transaction of $270,200.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 65,000 shares of company stock valued at $798,400. 2.90% of the stock is owned by company insiders.

A number of large investors have recently added to or reduced their stakes in FOLD. Sageworth Trust Co purchased a new stake in shares of Amicus Therapeutics during the 1st quarter valued at about $34,000. Strs Ohio boosted its holdings in shares of Amicus Therapeutics by 176.9% during the 1st quarter. Strs Ohio now owns 10,800 shares of the biopharmaceutical company’s stock valued at $146,000 after acquiring an additional 6,900 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Amicus Therapeutics during the 1st quarter valued at about $202,000. Amalgamated Bank boosted its holdings in shares of Amicus Therapeutics by 149.6% during the 4th quarter. Amalgamated Bank now owns 27,615 shares of the biopharmaceutical company’s stock valued at $265,000 after acquiring an additional 16,550 shares during the last quarter. Finally, Premier Asset Management LLC purchased a new stake in shares of Amicus Therapeutics during the 4th quarter valued at about $282,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Further Reading: The basics of gap trading strategies

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.